Further research is needed to validate our findings within HER2-positive breast cancer patients with clinically detectable, extensive DCIS, while carefully correlating radiology and pathology of the DCIS component pre- and post-NST. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.